Rafferty Asset Management, LLC Biotechnology

Rafferty Asset Management, LLC

$29.4 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$99.5B	$33.4 Million 0.11% of portfolio	75,108	Q2 2025 Added 6.04%
REGN Regeneron Pharmaceuticals, Inc.	$59.7B	$27.6 Million 0.09% of portfolio	52,628	Q2 2025 Added 17.73%
MRNA Moderna, Inc.	$10B	$10.9 Million 0.04% of portfolio	394,599	Q2 2025 Added 13.11%
INCY Incyte Corp	$18.2B	$10.7 Million 0.04% of portfolio	156,610	Q2 2025 Reduced 10.23%
ALNY Alnylam Pharmaceuticals, Inc.	$52.9B	$10.5 Million 0.04% of portfolio	32,196	Q2 2025 Reduced 27.79%
EXEL Exelixis, Inc.	$12.1B	$10.4 Million 0.04% of portfolio	236,792	Q2 2025 Added 0.77%
UTHR United Therapeutics Corp	$13.7B	$10.2 Million 0.03% of portfolio	35,558	Q2 2025 Reduced 1.12%
INSM Insmed Inc	$16.5B	$9.87 Million 0.03% of portfolio	98,110	Q2 2025 Reduced 32.79%
BMRN Biomarin Pharmaceutical Inc	$10.6B	$9.43 Million 0.03% of portfolio	171,523	Q2 2025 Added 27.79%
HALO Halozyme Therapeutics, Inc.	$8.95B	$9.4 Million 0.03% of portfolio	180,666	Q2 2025 Added 59.47%
BBIO Bridge Bio Pharma, Inc.	$7.28B	$8.5 Million 0.03% of portfolio	196,782	Q2 2025 Reduced 2.64%
BPMC Blueprint Medicines Corp	$7.73B	$7.76 Million 0.03% of portfolio	60,567	Q2 2025 Reduced 39.02%
MDGL Madrigal Pharmaceuticals, Inc.	$6.14B	$7.42 Million 0.03% of portfolio	24,533	Q2 2025 Reduced 17.96%
TGTX Tg Therapeutics, Inc.	$3.94B	$6.77 Million 0.02% of portfolio	188,220	Q2 2025 Added 3.5%
ROIV Roivant Sciences Ltd.	$8.15B	$6.74 Million 0.02% of portfolio	598,231	Q2 2025 Added 18.94%
IONS Ionis Pharmaceuticals Inc	$5.85B	$5.72 Million 0.02% of portfolio	144,770	Q2 2025 Reduced 17.86%
CYTK Cytokinetics Inc	$3.23B	$5.67 Million 0.02% of portfolio	171,581	Q2 2025 Added 14.76%
RVMD Revolution Medicines, Inc.	$3.09B	$5.63 Million 0.02% of portfolio	152,978	Q2 2025 Reduced 6.39%
CRSP Crispr Therapeutics Ag	$4.42B	$5.56 Million 0.02% of portfolio	114,348	Q2 2025 Reduced 21.7%
PCVX Vaxcyte, Inc.	$1.78B	$5.36 Million 0.02% of portfolio	164,823	Q2 2025 Added 25.04%
SWTX Spring Works Therapeutics, Inc.	$2.93B	$5.36 Million 0.02% of portfolio	114,006	Q2 2025 Added 2.78%
AKRO Akero Therapeutics, Inc.	$2.23B	$4.97 Million 0.02% of portfolio	93,128	Q2 2025 Added 25.71%
ADMA Adma Biologics, Inc.	$3.29B	$4.84 Million 0.02% of portfolio	265,928	Q2 2025 Added 19.07%
PTCT Ptc Therapeutics, Inc.	$3.24B	$4.77 Million 0.02% of portfolio	97,629	Q2 2025 Added 71.08%
KRYS Krystal Biotech, Inc.	$3.69B	$4.77 Million 0.02% of portfolio	34,665	Q2 2025 Added 43.48%
PTGX Protagonist Therapeutics, Inc	$2.68B	$4.45 Million 0.02% of portfolio	80,543	Q2 2025 Added 81.99%
SMMT Summit Therapeutics Inc.	$5.17B	$4.23 Million 0.01% of portfolio	198,853	Q2 2025 Reduced 13.45%
VKTX Viking Therapeutics, Inc.	$3.06B	$4.17 Million 0.01% of portfolio	157,499	Q2 2025 Reduced 14.3%
ACLX Arcellx, Inc.	$3.19B	$3.71 Million 0.01% of portfolio	56,371	Q2 2025 Reduced 3.65%
NUVL Nuvalent, Inc.	$3.29B	$3.69 Million 0.01% of portfolio	48,383	Q2 2025 Reduced 5.49%
RNA Avidity Biosciences, Inc.	$2.41B	$3.6 Million 0.01% of portfolio	126,882	Q2 2025 Reduced 12.38%
SRRK Scholar Rock Holding Corp	$1.66B	$3.54 Million 0.01% of portfolio	99,855	Q2 2025 Reduced 10.58%
RYTM Rhythm Pharmaceuticals, Inc.	$5.51B	$3.26 Million 0.01% of portfolio	51,611	Q2 2025 Reduced 10.6%
RARE Ultragenyx Pharmaceutical Inc.	$1.97B	$2.95 Million 0.01% of portfolio	81,096	Q2 2025 Reduced 8.69%
VCYT Veracyte, Inc.	$2.06B	$2.94 Million 0.01% of portfolio	108,822	Q2 2025 Reduced 1.93%
IMVT Immunovant, Inc.	$3.55B	$2.93 Million 0.01% of portfolio	106,470	Q2 2025 Reduced 23.31%
ACAD Acadia Pharmaceuticals Inc	$4.12B	$2.71 Million 0.01% of portfolio	125,737	Q2 2025 Reduced 37.22%
BCRX Biocryst Pharmaceuticals Inc	$1.55B	$2.7 Million 0.01% of portfolio	300,951	Q2 2025 Added 18.8%
CRNX Crinetics Pharmaceuticals, Inc.	$1.53B	$2.61 Million 0.01% of portfolio	90,756	Q2 2025 Reduced 11.14%
SRPT Sarepta Therapeutics, Inc.	$1.6B	$2.56 Million 0.01% of portfolio	149,760	Q2 2025 Added 51.11%
APLS Apellis Pharmaceuticals, Inc.	$2.63B	$2.49 Million 0.01% of portfolio	143,852	Q2 2025 Reduced 20.14%
FOLD Amicus Therapeutics, Inc.	$1.96B	$2.38 Million 0.01% of portfolio	415,038	Q2 2025 Added 63.55%
IDYA Ideaya Biosciences, Inc.	$1.13B	$2.31 Million 0.01% of portfolio	109,807	Q2 2025 Reduced 9.54%
ARWR Arrowhead Pharmaceuticals, Inc.	$1.88B	$2.24 Million 0.01% of portfolio	141,925	Q2 2025 Reduced 26.38%
ARQT Arcutis Biotherapeutics, Inc.	$887M	$2.16 Million 0.01% of portfolio	154,351	Q2 2025 Reduced 3.75%
BEAM Beam Therapeutics Inc.	$1.19B	$2.09 Million 0.01% of portfolio	122,832	Q2 2025 Added 2.47%
CPRX Catalyst Pharmaceuticals, Inc.	$2.09B	$2.08 Million 0.01% of portfolio	95,716	Q2 2025 Reduced 8.58%
VCEL Vericel Corp	$1.72B	$2.02 Million 0.01% of portfolio	47,489	Q2 2025 Reduced 0.43%
MIRM Mirum Pharmaceuticals, Inc.	$2.38B	$1.89 Million 0.01% of portfolio	37,207	Q2 2025 Reduced 28.25%
TVTX Travere Therapeutics, Inc.	$1.12B	$1.83 Million 0.01% of portfolio	123,854	Q2 2025 Reduced 14.6%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.